About Medriva Peptides & Our Editorial Policy
Quick answer
About Medriva Peptides and Editorial Policy is reviewed as a Medriva hub utility resource. The practical takeaway is to separate what is supported by human evidence from what is still theoretical, commercial, or regulatory-dependent. Evidence grade: n/a. Readers should use this page to frame a clinician conversation, not to self-prescribe, source, dose, or combine peptides.
For current regulatory movement, shortage status, warning letters, and compounding policy, check the Peptide Tracker before relying on older summaries.
Medriva Peptides is an evidence-based reference on therapeutic peptides, written and clinically reviewed by physicians and pharmacists. We do not sell peptides. We explain the science, the regulatory status, and how to talk to a licensed clinician if a therapy is right for you.
What this site is
Medriva Peptides is the peptide vertical of medriva.com. We publish original, evidence-graded, clinically-reviewed editorial content on therapeutic peptides and peptide-related drugs (GLP-1 receptor agonists, growth hormone secretagogues, recovery peptides, longevity peptides, and the regulatory landscape around them).
We are not a vendor. We do not sell peptides, drugs, or supplements. We do not operate a telehealth service, a pharmacy, or a compounding facility. We do not write prescriptions, hold patient health information, or make medical claims we wouldn't put in front of our own clinical reviewers.
What we do
- Editorial content. Profiles, comparisons, use-case hubs, safety pages, regulatory explainers, dispatches (long-form newsletters), and a daily news layer ("The Daily Brief").
- An email newsletter — "The Medriva Peptide Brief" — long-form dispatches and short-form roundups.
- An affiliate program with vetted telehealth platforms and compounding pharmacies. We may earn a commission if you click an affiliate link and purchase, at no extra cost to you. This does not affect our editorial recommendations. We only link to partners we have vetted, and we publish our affiliate policy and sponsorship policy below.
- A vendor evaluation framework. A neutral, evidence-based methodology for evaluating compounding pharmacies and research-use-only vendors. We do not publish a vendor scorecard in v1; we publish the methodology and link out to public Certificate-of-Analysis (COA) databases.
What we do not do
- We do not sell peptides, drugs, or supplements.
- We do not operate a telehealth or prescribing service.
- We do not operate a pharmacy or compounding facility.
- We do not provide medical advice, diagnoses, or treatment plans.
- We do not hold, store, or process patient health information.
- We do not publish before/after photos, transformation stories, or celebrity endorsements.
Affiliate disclosure
Some links on this page — and across medriva.com/ — are affiliate links. If you click one and make a purchase, we may earn a commission. This does not affect our editorial recommendations. We only link to partners we have vetted, and we disclose every partnership in this policy.
We follow the FTC Endorsement Guides (16 CFR Part 255):
- Affiliate links carry
rel="sponsored"so they are machine-readable. - Affiliate disclosures are above the fold, not buried in the footer.
- We only recommend products and services our clinical reviewers would recommend to a family member.
- Affiliate relationships do not determine what we publish, what we say, or which products we cover.
Our affiliate partners are listed in our partner matrix (artifact under build/newsletter workflow/partner-matrix.md). We publish commission rates and cookie windows. We do not promote per-patient-referral arrangements (which would cross into Anti-Kickback Statute territory).
Sponsored content
"Sponsored" content is clearly labeled, in the title prefix, above the fold, and in the page's structured data. Sponsored posts are reviewed by our clinical reviewers against the same standard we apply to editorial content, with a few differences:
- The sponsor pays Medriva for the placement; the sponsor does not write the copy.
- All claims in a sponsored post must be defensible and supported by citations.
- Medriva retains full editorial control; we will refuse a sponsor's draft if it does not meet our editorial standard.
- All links in a sponsored post carry
rel="sponsored".
We do not run sponsored content that promotes a non-FDA-approved compound for a specific clinical use, contains before/after imagery, or makes claims we would not make in our own editorial content.
Editorial policy (summary)
Our full editorial policy is published at /about-and-editorial-policy/ and lives in our build artifacts. The short version:
- E-E-A-T. Every page has a named author, a named clinical reviewer, citations, and a "last reviewed" date.
- Evidence grading. Every medical claim is graded Strong / Moderate / Preliminary / Anecdotal / Unestablished using a 5-grade scale.
- Banned claims. We do not publish efficacy promises, before/after framing, off-label promotion, dosing protocols for non-FDA-approved compounds, celebrity tie-ins, or testimonial photos.
- Citations. Profiles require ≥ 5 peer-reviewed references; comparisons ≥ 8; pillars ≥ 25.
- Dosing for non-approved compounds. We do not publish "typical dose" tables for compounds that are not FDA-approved. We use an explicit "dosing is unestablished" template that points readers to a clinician and to our vendor evaluation framework.
- Updates. A "last reviewed" date is on every page. Material evidence or regulatory changes trigger a re-review within 5 business days.
Clinical reviewers
Our clinical reviewers are licensed U.S. clinicians (MD, DO, PharmD, NP, or PA with prescribing authority) with verifiable experience in endocrinology, weight management, longevity medicine, sports medicine, dermatology, or pharmacy compounding. They are independent contractors — not employees — and they have no financial relationship with any Medriva affiliate partner.
Reviewer byline: name, credentials, state, NPI, last-reviewed date. Conflict-of-interest disclosure is on file and re-attested annually.
See our full reviewer panel and methodology →
How to contact us
- General: editor@medriva.com
- Corrections: corrections@medriva.com — we aim to acknowledge within 2 business days and correct factual errors within 5 business days.
- Press: press@medriva.com
- Partnership inquiries: partnerships@medriva.com
Medical disclaimer
The content on Medriva Peptides is for informational and educational purposes only. It is not medical advice and is not a substitute for consultation with a licensed clinician. Do not start, stop, or change any therapy based on what you read here. Always consult a qualified healthcare provider in your state before making any decisions about peptides, hormones, or any medication. If you are experiencing a medical emergency, call 911 or your local emergency number.
Sign-off
This page is reviewed at least every 6 months, and immediately after any regulatory enforcement action that touches our category.
| Role | Date | Sign-off |
|---|---|---|
| Head of Content | June 5, 2026 | Approved |
| Clinical review lead | June 5, 2026 | Approved |
| Legal counsel | Pending | Scheduled review |
Frequently Asked Questions
What is the main takeaway on About Medriva Peptides and Editorial Policy?
The main takeaway is that About Medriva Peptides and Editorial Policy should be evaluated through evidence quality, safety signals, regulatory status, and clinical fit. Stronger claims need stronger human data and clear source support.
Is About Medriva Peptides and Editorial Policy medical advice?
No. This page is educational and is not a diagnosis, treatment plan, prescription, or dosing recommendation. Personal decisions should be made with a licensed clinician who understands your medical history.
What should I verify before acting on this topic?
Verify whether the compound or product is FDA-approved for the intended use, whether the evidence applies to your situation, whether there are contraindications or interactions, and whether the latest regulator updates change access or safety assumptions.
Where should I check for new peptide updates?
Use the Peptide Tracker for current FDA actions, warning letters, OIG oversight items, WADA updates, compounding policy, and pharmacy-oversight signals.
